MedPath

Buccal Versus Vaginal Misoprostol In Combination With Foley Bulb

Early Phase 1
Completed
Conditions
Induction of Labor
Interventions
Registration Number
NCT03976037
Lead Sponsor
Christiana Care Health Services
Brief Summary

Combined misoprostol and Foley bulb catheter has been shown to be an effective induction method. However, optimal route of administration for misoprostol has not been established.

Therefore, the purpose of this study is to compare the effectiveness and safety of combination buccal miso-foley to combination vaginal miso-foley for third trimester cervical ripening and induction of labor.

Detailed Description

This randomized controlled trial of consenting women undergoing induction of labor with combined misoprostol and Foley catheter seeks to efficacy of vaginal versus buccal misoprostol route of administration.

This project will include 216 women presenting at Christiana Care Health System. Women will be included if they are at least 37 weeks gestation, have a singleton pregnancy, have intact membranes and are undergoing an induction of labor using a Foley catheter combined with misoprostol. Following admission, women will be randomized into either vaginal or buccal misoprostol.

Women will be randomized with equal probability to the intervention group using block randomization stratified by party.

Patients will receive 25 micrograms of misoprostol along with the insertion of a16F Foley catheter. Misoprostol can be repeated up to five additional times for a maximum of 24 hours or a total of 6 doses if the patient is not contracting more than 3 times per 10 minutes. The remainder of labor management will be at the discretion of each woman's obstetric provider.

Prior to discharge from the hospital, baseline demographic and clinical data will be obtained via chart review

Recruitment & Eligibility

Status
COMPLETED
Sex
Female
Target Recruitment
216
Inclusion Criteria
  • ≥18 years of age
  • full term (≥37 weeks) gestations determined by routine obstetrical guidelines
  • singleton gestation in cephalic presentation
  • Both nulliparous and multiparous women
  • Intact membranes
  • Cervical dilation ≤2cm
Exclusion Criteria
  • Any contraindication to a vaginal delivery or to misoprostol
  • fetal demise
  • Multifetal gestation
  • prior uterine surgery, previous cesarean section
  • Tachysystole was defined as at least 6 contractions in 10 minutes for 2 consecutive 10-minute periods
  • women with HIV, and women with medical conditions requiring an assisted second stage
  • Additional exclusion criteria were as follows: category 3 fetal heart rate tracing, hemolysis elevated liver enzymes and low platelets (HELLP) syndrome or eclampsia, growth restriction <10th percentile (based on Hadlock growth curves) with reversal of flow in umbilical artery Doppler studies, and growth restriction <5th percentile with elevated, absent, or reversal of flow in umbilical artery Doppler studies

As described in previous research (Levine LD, Downes KL, Elovitz MA, Parry S, Sammel MD, Srinivas SK. Mechanical and Pharmacologic Methods of Labor Induction: A Randomized Controlled Trial. Obstet Gynecol. 2016;128(6):1357-1364)

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Buccal Misoprostol in combination with foley bulbMisoprostolmisoprostol and a cervical Foley placed. Patients will receive 25 micrograms of buccal misoprostol along with the insertion of a16F Foley catheter with stylet. The Foley balloon catheter will be filled with 30cc balloon inserted digitally or by direct visualization with a speculum. The Foley bulb will be placed just above the level of the internal os and inflated with 30cc of sterile water. Buccal misoprostol can be repeated up to five additional times for a maximum of 24 hours or a total of 6 doses if the patient is not contracting more than 3 times per 10 minutes. If the patient is contracting more than 3 times per 10 minutes after 6 hours, oxytocin protocol is initiated.
Vaginal Misoprostol in combination with foley bulbMisoprostolWomen in the vaginal misoprostol-cervical Foley group will have both misoprostol and a cervical Foley placed. Patients will receive 25 micrograms of misoprostol per vagina along with the insertion of a16F Foley catheter with a stylet. The Foley balloon catheter will be filled with 30cc balloon inserted digitally or by direct visualization with a speculum. The Foley bulb will be placed just above the level of the internal os and inflated with 30cc of sterile water. Vaginal misoprostol can be repeated up to five additional times for a maximum of 24 hours or a total of 6 doses if the patient is not contracting more than 3 times per 10 minutes. If the patient is contracting more than 3 times per 10 minutes after 6 hours, oxytocin protocol is initiated.
Primary Outcome Measures
NameTimeMethod
time to delivery (hours) definedthrough study completion, an average of 2 year

as time from initiation of induction method to delivery time, regardless of mode of delivery.

Secondary Outcome Measures
NameTimeMethod
Rate of Cesarean deliverythrough study completion, an average of 2 year

yes/no

Indication for cesarean deliverythrough study completion, an average of 2 year

The reason for induction: NRFHT, arrest of dilation, arrest of descent, failed IOL, other

Rate of 3rd/4th degree perineal lacerationthrough study completion, an average of 2 year

yes/no

Rate of Maternal Blood transfusionthrough study completion, an average of 2 year

yes/no

Rate of Maternal Deaththrough study completion, an average of 2 year

yes/no

Rate of Chorioamnionitisthrough study completion, an average of 2 year

the presence of maternal fever ≥100·4°f in the presence of maternal or fetal tachycardia or fundal tenderness

Rate of terbutaline usethrough study completion, an average of 2 year

yes/no

Rate of Intrauterine pressure catheter usethrough study completion, an average of 2 year

yes/no

Rate of head cooling.From time of delivery to hospital discharge; up to 6 weeks

yes/no

Rate of Intensive care unit admissionthrough study completion, an average of 2 year

yes/no

Rate of Analgesia usethrough study completion, an average of 2 year

yes/no

Rate of Intraventricular hemorrhage grade 3 or 4From time of delivery to hospital discharge; up to 6 weeks

yes/no

Time to active laborthrough study completion, an average of 2 year

s time from initiation of induction method to dilatation ≥6cm

Maternal length of staythrough study completion, an average of 2 year

defined as length of time from admission for induction to discharge postpartum, days

Rate of Venous thromboembolismthrough study completion, an average of 2 year

yes/no

Rate of Hysterectomythrough study completion, an average of 2 year

yes/no

Rate of Hypoxic ischemic encephalopathyFrom time of delivery to hospital discharge; up to 6 weeks

yes/no

Rate of Wound separation-infectionFrom time of delivery to time of hospital discharge; up to 6 weeks

the need for additional wound closure or the need for antibiotics

Rate of Severe respiratory distress syndromeFrom time of delivery to hospital discharge; up to 6 weeks

defined as intubation and mechanical ventilation for a minimum of 12 hours

Rate of Neonatal blood transfusionFrom time of delivery to hospital discharge; up to 6 weeks

yes/no

Rate of Endometritisthrough study completion, an average of 2 year

yes/no; fundal tenderness and fever that required treatment with antibiotics

Rate of Amnioinfusionthrough study completion, an average of 2 year

yes/no

Rate of Culture proven-presumed neonatal sepsisFrom time of delivery to hospital discharge; up to 6 weeks

yes/no

Rate of NICU admissionFrom time of delivery to hospital discharge; up to 6 weeks

yes/no

Rate of Necrotizing enterocolitisFrom time of delivery to hospital discharge; up to 6 weeks

yes/no

Trial Locations

Locations (1)

Christiana Care Health Systems

🇺🇸

Newark, Delaware, United States

© Copyright 2025. All Rights Reserved by MedPath